Monarch Therapeutics, SNAP Biosciences enter licensing agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2025
0mins
Licensing Agreement: SNAP Biosciences and Monarch Therapeutics have entered into a licensing agreement to develop and commercialize the Snap-Car NK cell therapy platform in oncology, utilizing Monarch's small molecule adaptor technology.
Enhanced Technology: This collaboration enhances the functionality of SNAP's universal CAR-based receptor platform, allowing for greater precision and flexibility in therapeutic applications, while Monarch will receive upfront payments and royalties from future sales.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COEP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COEP
About COEP
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Continue Reading
Coeptis Therapeutics Secures SEC Approval for Merger with Z Squared Inc.
- Merger Progress: Coeptis Therapeutics announced that its registration statement for the merger with Z Squared has been approved by the SEC, marking a significant step forward that is expected to enhance the company's market competitiveness.
- Shareholder Meeting Arrangement: The company will hold a special shareholder meeting on January 30, 2026, to discuss the merger, with the proxy statement and prospectus being mailed to shareholders on January 7, ensuring transparency and shareholder engagement.
- Listing Application Update: The combined company has applied for a Nasdaq listing, and while approval is pending, this move indicates the company's proactive approach to future capital markets, which, if successful, will enhance its market recognition.
- Technology and Business Integration: By merging with Z Squared, Coeptis aims to integrate its biopharmaceutical technologies with cryptocurrency mining operations, driving innovation and diversification to bolster long-term growth potential.
Continue Reading